452 related articles for article (PubMed ID: 18644798)
1. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.
Mizobuchi M; Finch JL; Martin DR; Slatopolsky E
Kidney Int; 2007 Sep; 72(6):709-15. PubMed ID: 17597697
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of vitamin D analogs on vascular calcification.
Cardús A; Panizo S; Parisi E; Fernandez E; Valdivielso JM
J Bone Miner Res; 2007 Jun; 22(6):860-6. PubMed ID: 17352647
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism.
Mizobuchi M; Ogata H; Hatamura I; Koiwa F; Saji F; Shiizaki K; Negi S; Kinugasa E; Ooshima A; Koshikawa S; Akizawa T
Nephrol Dial Transplant; 2006 Apr; 21(4):911-6. PubMed ID: 16384827
[TBL] [Abstract][Full Text] [Related]
5. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
6. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
Wu-Wong JR; Melnick J
Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
[TBL] [Abstract][Full Text] [Related]
7. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
8. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification.
Wu-Wong JR; Noonan W; Ma J; Dixon D; Nakane M; Bolin AL; Koch KA; Postl S; Morgan SJ; Reinhart GA
J Pharmacol Exp Ther; 2006 Jul; 318(1):90-8. PubMed ID: 16603671
[TBL] [Abstract][Full Text] [Related]
9. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
Goldenberg MM
Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
[TBL] [Abstract][Full Text] [Related]
10. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
Cozzolino M; Staniforth ME; Liapis H; Finch J; Burke SK; Dusso AS; Slatopolsky E
Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
[TBL] [Abstract][Full Text] [Related]
11. Effects of new vitamin D analogues on parathyroid function in chronically uraemic rats with secondary hyperparathyroidism.
Hruby M; Ureña P; Mannstadt M; Schmitt F; Lacour B; Drüeke TB
Nephrol Dial Transplant; 1996 Sep; 11(9):1781-6. PubMed ID: 8918622
[TBL] [Abstract][Full Text] [Related]
12. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
[TBL] [Abstract][Full Text] [Related]
13. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
[TBL] [Abstract][Full Text] [Related]
14. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
15. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.
Joist HE; Ahya SN; Giles K; Norwood K; Slatopolsky E; Coyne DW
Clin Nephrol; 2006 May; 65(5):335-41. PubMed ID: 16724654
[TBL] [Abstract][Full Text] [Related]
17. Highly concentrated calcitriol and its analogues induce apoptosis of parathyroid cells and regression of the hyperplastic gland--study in rats.
Shiizaki K; Hatamura I; Negi S; Sakaguchi T; Saji F; Imazeki I; Kusano E; Shigematsu T; Akizawa T
Nephrol Dial Transplant; 2008 May; 23(5):1529-36. PubMed ID: 18156462
[TBL] [Abstract][Full Text] [Related]
18. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats.
Lopez I; Mendoza FJ; Aguilera-Tejero E; Perez J; Guerrero F; Martin D; Rodriguez M
Kidney Int; 2008 Feb; 73(3):300-7. PubMed ID: 18004298
[TBL] [Abstract][Full Text] [Related]
19. Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism.
Sanchez CP; He YZ
J Am Soc Nephrol; 2005 Apr; 16(4):929-38. PubMed ID: 15728789
[TBL] [Abstract][Full Text] [Related]
20. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
Slatopolsky E; Finch JL; Brown AJ; Ritter CS; Mizobuchi M; Plum LA; Clagett-Dame M; Sicinski RR; DeLuca HF
J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
